Hyaluronic acid-based nanoparticles for pulmonary delivery of poorly soluble drugs

IF 6.7 3区材料科学 Q2 CHEMISTRY, PHYSICAL

Colloid and Interface Science Communications Pub Date : 2026-01-01 Epub Date: 2026-01-06 DOI:10.1016/j.colcom.2025.100868

Candelaria Ines Camara , Caterina Ricci , Laura Bertocchi , Rosaria Bassi , Annalisa Bianchera , Ruggero Bettini , Elena Del Favero

{"title":"Hyaluronic acid-based nanoparticles for pulmonary delivery of poorly soluble drugs","authors":"Candelaria Ines Camara , Caterina Ricci , Laura Bertocchi , Rosaria Bassi , Annalisa Bianchera , Ruggero Bettini , Elena Del Favero","doi":"10.1016/j.colcom.2025.100868","DOIUrl":null,"url":null,"abstract":"<div><div>The delivery of poorly soluble drugs poses significant challenges in pharmacotherapy, particularly for corticosteroids. This study investigates the development of hyaluronic acid-based nanoparticles to enhance the solubility and bioavailability of dexamethasone. Hyaluronic acid-dexamethasone formulations, (HAm 15–30 kDa and HAl 750–1000 kDa), were produced as stable powders to be resuspended. We characterized the nanoparticles formed after resuspension by laser-light and X-ray scattering. Nanoparticles showed nanometric size, good stability, a core-shell arrangement, and muco-inert properties. We evaluated the interaction of nanoparticles with lung surfactant models, by nebulization of formulations on DPPC Langmuir monolayers to mimic their effects on alveolar interfaces when administered via nebulization. They showed good biocompatibility and enhanced anti-inflammatory response, as assessed by pro-inflammatory cytokine TNF-α release in LPS-stimulated macrophages. The favorable structural and biopharmaceutical characteristics of HA-based formulations can be exploited to improve the delivery of poorly soluble drugs to the lungs by inhalation.</div></div>","PeriodicalId":10483,"journal":{"name":"Colloid and Interface Science Communications","volume":"70 ","pages":"Article 100868"},"PeriodicalIF":6.7000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloid and Interface Science Communications","FirstCategoryId":"88","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2215038225000524","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

The delivery of poorly soluble drugs poses significant challenges in pharmacotherapy, particularly for corticosteroids. This study investigates the development of hyaluronic acid-based nanoparticles to enhance the solubility and bioavailability of dexamethasone. Hyaluronic acid-dexamethasone formulations, (HAm 15–30 kDa and HAl 750–1000 kDa), were produced as stable powders to be resuspended. We characterized the nanoparticles formed after resuspension by laser-light and X-ray scattering. Nanoparticles showed nanometric size, good stability, a core-shell arrangement, and muco-inert properties. We evaluated the interaction of nanoparticles with lung surfactant models, by nebulization of formulations on DPPC Langmuir monolayers to mimic their effects on alveolar interfaces when administered via nebulization. They showed good biocompatibility and enhanced anti-inflammatory response, as assessed by pro-inflammatory cytokine TNF-α release in LPS-stimulated macrophages. The favorable structural and biopharmaceutical characteristics of HA-based formulations can be exploited to improve the delivery of poorly soluble drugs to the lungs by inhalation.

Abstract Image

查看原文本刊更多论文

透明质酸纳米颗粒用于肺输送难溶性药物

难溶性药物的递送给药物治疗带来了重大挑战，尤其是皮质类固醇。本研究探讨了透明质酸纳米颗粒的发展，以提高地塞米松的溶解度和生物利用度。透明质酸-地塞米松制剂（ham15 - 30kda和HAl 750-1000 kDa）制成稳定的粉末进行重悬。我们用激光和x射线散射对再悬浮后形成的纳米颗粒进行了表征。纳米颗粒具有纳米尺寸、良好的稳定性、核-壳排列和黏液惰性等特性。我们评估了纳米颗粒与肺表面活性剂模型的相互作用，通过雾化DPPC朗缪尔单层来模拟它们在雾化给药时对肺泡界面的影响。通过在lps刺激的巨噬细胞中释放促炎细胞因子TNF-α来评估，它们表现出良好的生物相容性和增强的抗炎反应。可以利用ha基制剂的有利结构和生物制药特性来改善通过吸入将难溶性药物输送到肺部。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colloid and Interface Science Communications Materials Science-Materials Chemistry

CiteScore

9.40

自引率

6.70%

发文量

125

审稿时长

43 days

期刊介绍： Colloid and Interface Science Communications provides a forum for the highest visibility and rapid publication of short initial reports on new fundamental concepts, research findings, and topical applications at the forefront of the increasingly interdisciplinary area of colloid and interface science.